---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-028556"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2022-10-17T23:59:59+00:00"
generated_at: "2026-06-23T03:14:14.127350+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio terminates Chief Medical Officer Michael Dawson, effective Oct 11, 2022

## Summary
- Michael Dawson, MD, terminated as Chief Medical Officer effective October 11, 2022.
- No successor or interim CMO named in the filing.
- Departure may impact clinical development strategy for Palisade Bio (PALI).

## SEC filing metadata
- accession: 0001493152-22-028556
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2022-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028556/0001493152-22-028556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028556/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-028556
- JSON: https://secwatch.observer/filing/0001493152-22-028556.json
- Plain text: https://secwatch.observer/filing/0001493152-22-028556.txt

## Key facts
- Executive change
  Michael Dawson was terminated as Chief Medical Officer at PALISADE BIO, INC..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: the employment of Michael Dawson, MD, was terminated by Palisade Bio, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028556/0001493152-22-028556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.